Wedbush Securities Inc. Invests $236,000 in Agilent Technologies, Inc. $A

Wedbush Securities Inc. bought a new position in shares of Agilent Technologies, Inc. (NYSE:A) during the second quarter, HoldingsChannel.com reports. The firm bought 2,000 shares of the medical research company’s stock, valued at approximately $236,000.

Several other hedge funds have also recently bought and sold shares of A. Rovin Capital UT ADV raised its holdings in Agilent Technologies by 8.1% during the second quarter. Rovin Capital UT ADV now owns 4,500 shares of the medical research company’s stock worth $531,000 after acquiring an additional 339 shares in the last quarter. Harvest Portfolios Group Inc. raised its holdings in Agilent Technologies by 24.3% in the 2nd quarter. Harvest Portfolios Group Inc. now owns 506,999 shares of the medical research company’s stock valued at $59,831,000 after acquiring an additional 99,168 shares in the last quarter. Savant Capital LLC increased its holdings in Agilent Technologies by 665.2% in the 2nd quarter. Savant Capital LLC now owns 27,477 shares of the medical research company’s stock valued at $3,243,000 after buying an additional 23,886 shares during the period. Modera Wealth Management LLC increased its stake in shares of Agilent Technologies by 6.1% in the 2nd quarter. Modera Wealth Management LLC now owns 30,930 shares of the medical research company’s stock valued at $3,650,000 after purchasing an additional 1,771 shares during the last quarter. Finally, Sienna Gestion boosted its stake in shares of Agilent Technologies by 10.3% in the 2nd quarter. Sienna Gestion now owns 78,534 shares of the medical research company’s stock valued at $8,461,000 after purchasing an additional 7,315 shares in the last quarter. 87.41% of the stock is currently owned by institutional investors and hedge funds.

Agilent Technologies Trading Down 3.1%

NYSE A opened at $146.75 on Friday. The stock’s fifty day moving average price is $137.27 and its 200-day moving average price is $123.50. The company has a current ratio of 2.25, a quick ratio of 1.71 and a debt-to-equity ratio of 0.53. The stock has a market cap of $41.60 billion, a P/E ratio of 34.45, a P/E/G ratio of 4.67 and a beta of 1.29. Agilent Technologies, Inc. has a 12 month low of $96.43 and a 12 month high of $153.84.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, hitting analysts’ consensus estimates of $1.37. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The firm had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.67 billion. During the same period in the previous year, the business posted $1.32 earnings per share. The business’s revenue for the quarter was up 10.1% on a year-over-year basis. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. As a group, equities analysts forecast that Agilent Technologies, Inc. will post 5.58 EPS for the current fiscal year.

Agilent Technologies Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, October 22nd. Investors of record on Tuesday, September 30th were given a $0.248 dividend. This represents a $0.99 annualized dividend and a yield of 0.7%. The ex-dividend date was Tuesday, September 30th. Agilent Technologies’s payout ratio is currently 23.24%.

Analyst Ratings Changes

Several brokerages recently issued reports on A. Rothschild & Co Redburn began coverage on Agilent Technologies in a research report on Wednesday, October 8th. They set a “buy” rating and a $165.00 target price for the company. JPMorgan Chase & Co. upped their price objective on shares of Agilent Technologies from $155.00 to $165.00 and gave the company an “overweight” rating in a report on Thursday, October 9th. Robert W. Baird increased their price objective on Agilent Technologies from $141.00 to $142.00 and gave the stock an “outperform” rating in a research note on Thursday, August 28th. Wall Street Zen upgraded Agilent Technologies from a “hold” rating to a “buy” rating in a research note on Friday, October 3rd. Finally, UBS Group raised Agilent Technologies from a “neutral” rating to a “buy” rating and upped their price target for the company from $130.00 to $170.00 in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $149.62.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.